ARTERRA BIOSCIENCE SPA (ARBS.MI) Fundamental Analysis & Valuation

BIT:ARBS • IT0005386369

Current stock price

3.12 EUR
+0.4 (+14.71%)
Last:

This ARBS.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. ARBS.MI Profitability Analysis

1.1 Basic Checks

  • ARBS had positive earnings in the past year.
  • ARBS had a positive operating cash flow in the past year.
  • Each year in the past 5 years ARBS has been profitable.
  • In the past 5 years ARBS always reported a positive cash flow from operatings.
ARBS.MI Yearly Net Income VS EBIT VS OCF VS FCFARBS.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M

1.2 Ratios

  • ARBS has a Return On Assets of 13.59%. This is amongst the best in the industry. ARBS outperforms 88.10% of its industry peers.
  • With an excellent Return On Equity value of 16.33%, ARBS belongs to the best of the industry, outperforming 84.52% of the companies in the same industry.
  • ARBS has a Return On Invested Capital of 12.78%. This is amongst the best in the industry. ARBS outperforms 85.71% of its industry peers.
Industry RankSector Rank
ROA 13.59%
ROE 16.33%
ROIC 12.78%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARBS.MI Yearly ROA, ROE, ROICARBS.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • ARBS's Profit Margin of 42.38% is amongst the best of the industry. ARBS outperforms 92.86% of its industry peers.
  • In the last couple of years the Profit Margin of ARBS has grown nicely.
  • Looking at the Operating Margin, with a value of 46.43%, ARBS belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
  • In the last couple of years the Operating Margin of ARBS has remained more or less at the same level.
  • ARBS has a Gross Margin of 63.60%. This is comparable to the rest of the industry: ARBS outperforms 54.76% of its industry peers.
  • ARBS's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 46.43%
PM (TTM) 42.38%
GM 63.6%
OM growth 3Y-2.56%
OM growth 5Y-0.49%
PM growth 3Y2.84%
PM growth 5Y1.89%
GM growth 3Y-2.93%
GM growth 5Y2.33%
ARBS.MI Yearly Profit, Operating, Gross MarginsARBS.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ARBS.MI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ARBS is creating some value.
  • There is no outstanding debt for ARBS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ARBS.MI Yearly Shares OutstandingARBS.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ARBS.MI Yearly Total Debt VS Total AssetsARBS.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • ARBS has an Altman-Z score of 7.52. This indicates that ARBS is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ARBS (7.52) is better than 78.57% of its industry peers.
  • ARBS has a debt to FCF ratio of 0.30. This is a very positive value and a sign of high solvency as it would only need 0.30 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.30, ARBS belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
  • ARBS has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • ARBS has a better Debt to Equity ratio (0.02) than 73.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.3
Altman-Z 7.52
ROIC/WACC1.61
WACC7.96%
ARBS.MI Yearly LT Debt VS Equity VS FCFARBS.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.3 Liquidity

  • A Current Ratio of 7.40 indicates that ARBS has no problem at all paying its short term obligations.
  • The Current ratio of ARBS (7.40) is better than 85.71% of its industry peers.
  • ARBS has a Quick Ratio of 6.31. This indicates that ARBS is financially healthy and has no problem in meeting its short term obligations.
  • ARBS has a better Quick ratio (6.31) than 85.71% of its industry peers.
Industry RankSector Rank
Current Ratio 7.4
Quick Ratio 6.31
ARBS.MI Yearly Current Assets VS Current LiabilitesARBS.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ARBS.MI Growth Analysis

3.1 Past

  • ARBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.48%, which is quite impressive.
  • ARBS shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.34% yearly.
  • The Revenue has grown by 13.44% in the past year. This is quite good.
  • The Revenue has been growing by 10.50% on average over the past years. This is quite good.
EPS 1Y (TTM)37.48%
EPS 3Y14.26%
EPS 5Y13.34%
EPS Q2Q%109.79%
Revenue 1Y (TTM)13.44%
Revenue growth 3Y9.27%
Revenue growth 5Y10.5%
Sales Q2Q%14.28%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ARBS.MI Yearly Revenue VS EstimatesARBS.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M

More info and screens

Find the best growth stocksShow best growing peers

5

4. ARBS.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 10.40, the valuation of ARBS can be described as reasonable.
  • Based on the Price/Earnings ratio, ARBS is valued cheaper than 92.86% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of ARBS to the average of the S&P500 Index (27.87), we can say ARBS is valued rather cheaply.
Industry RankSector Rank
PE 10.4
Fwd PE N/A
ARBS.MI Price Earnings VS Forward Price EarningsARBS.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ARBS indicates a rather cheap valuation: ARBS is cheaper than 92.86% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ARBS indicates a rather cheap valuation: ARBS is cheaper than 89.29% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 20.04
EV/EBITDA 7.33
ARBS.MI Per share dataARBS.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

  • ARBS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.78
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. ARBS.MI Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 4.93%, ARBS is a good candidate for dividend investing.
  • ARBS's Dividend Yield is rather good when compared to the industry average which is at 0.70. ARBS pays more dividend than 97.62% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.81, ARBS pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.93%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 44.46% of the earnings are spent on dividend by ARBS. This is a bit on the high side, but may be sustainable.
DP44.46%
EPS Next 2YN/A
EPS Next 3YN/A
ARBS.MI Yearly Income VS Free CF VS DividendARBS.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M
ARBS.MI Dividend Payout.ARBS.MI Dividend Payout, showing the Payout Ratio.ARBS.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ARBS.MI Fundamentals: All Metrics, Ratios and Statistics

ARTERRA BIOSCIENCE SPA

BIT:ARBS (4/7/2026, 7:00:00 PM)

3.12

+0.4 (+14.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.16%
Inst Owner ChangeN/A
Ins Owners40.85%
Ins Owner ChangeN/A
Market Cap20.78M
Revenue(TTM)4.49M
Net Income(TTM)1.90M
Analysts82.86
Price Target3.88 (24.36%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.93%
Yearly Dividend0.11
Dividend Growth(5Y)N/A
DP44.46%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 10.4
Fwd PE N/A
P/S 4.62
P/FCF 20.04
P/OCF 10.93
P/B 1.78
P/tB 1.79
EV/EBITDA 7.33
EPS(TTM)0.3
EY9.62%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.16
FCFY4.99%
OCF(TTM)0.29
OCFY9.15%
SpS0.67
BVpS1.75
TBVpS1.75
PEG (NY)N/A
PEG (5Y)0.78
Graham Number3.43785 (10.19%)
Profitability
Industry RankSector Rank
ROA 13.59%
ROE 16.33%
ROCE 16.27%
ROIC 12.78%
ROICexc 17.47%
ROICexgc 17.53%
OM 46.43%
PM (TTM) 42.38%
GM 63.6%
FCFM 23.07%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.56%
OM growth 5Y-0.49%
PM growth 3Y2.84%
PM growth 5Y1.89%
GM growth 3Y-2.93%
GM growth 5Y2.33%
F-Score6
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.3
Debt/EBITDA 0.11
Cap/Depr 269.44%
Cap/Sales 19.23%
Interest Coverage 250
Cash Conversion 78.96%
Profit Quality 54.44%
Current Ratio 7.4
Quick Ratio 6.31
Altman-Z 7.52
F-Score6
WACC7.96%
ROIC/WACC1.61
Cap/Depr(3y)122.55%
Cap/Depr(5y)102.25%
Cap/Sales(3y)9.39%
Cap/Sales(5y)9.38%
Profit Quality(3y)64.74%
Profit Quality(5y)71.37%
High Growth Momentum
Growth
EPS 1Y (TTM)37.48%
EPS 3Y14.26%
EPS 5Y13.34%
EPS Q2Q%109.79%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.44%
Revenue growth 3Y9.27%
Revenue growth 5Y10.5%
Sales Q2Q%14.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y62.77%
EBIT growth 3Y6.47%
EBIT growth 5Y9.97%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y285.3%
FCF growth 3Y5.88%
FCF growth 5Y73.71%
OCF growth 1Y87.22%
OCF growth 3Y12.6%
OCF growth 5Y32.93%

ARTERRA BIOSCIENCE SPA / ARBS.MI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ARTERRA BIOSCIENCE SPA?

ChartMill assigns a fundamental rating of 7 / 10 to ARBS.MI.


What is the valuation status of ARTERRA BIOSCIENCE SPA (ARBS.MI) stock?

ChartMill assigns a valuation rating of 5 / 10 to ARTERRA BIOSCIENCE SPA (ARBS.MI). This can be considered as Fairly Valued.


How profitable is ARTERRA BIOSCIENCE SPA (ARBS.MI) stock?

ARTERRA BIOSCIENCE SPA (ARBS.MI) has a profitability rating of 8 / 10.


Can you provide the financial health for ARBS stock?

The financial health rating of ARTERRA BIOSCIENCE SPA (ARBS.MI) is 9 / 10.


How sustainable is the dividend of ARTERRA BIOSCIENCE SPA (ARBS.MI) stock?

The dividend rating of ARTERRA BIOSCIENCE SPA (ARBS.MI) is 6 / 10 and the dividend payout ratio is 44.46%.